medigraphic.com
ISSN 1561-2937 (Print)

2016, Number 2

<< Back

Rev Cubana Cardiol Cir Cardiovasc 2016; 22 (2)

Preoperative use of Atorvastatin in patients with factors of coronary risk in major no cardiac surgery

Labrada DA, Machado VM, Crespo ÁA

Language: Spanish
References: 30
Page: 116-123
PDF size: 659.61 Kb.


ABSTRACT

Introduction: Cardiovascular events are the main complication in the perioperative period. Statins are the drugs of choice in primary and secondary prevention of cardiovascular diseases at the lipid-lowering effect. Objective: To determine the effect that produces the preoperative administration of atorvastatin in patient with factors of risk coronary undergoing major no cardiac surgery. Methods: Was carried out a descriptive, longitudinal, randomized and prospective study in patient bigger than 60 years intervened surgically in the University Hospital of “Gral. Calixto García” from 2011 to 2014. In all they were identified more than three factors of coronary risk and they conformed to two groups. One received one month before the surgery 80 mg of atorvastatin daily and other not. The evaluated variables were: TAM, FC, segment ST, variation of the QT and cardiovascular complications in different moments. Results: The biggest quantity in patients was feminine between 65 and 74 years. The most frequent factors of risk were the arterial hypertension, the hypercholesterolemia, and the tabaquismo. The TAM, FC and segment ST didn't modify in a significant way in none of the two groups. The group that not receives statins presented bigger incidence of lengthening of the QT in the postopera-tive and bigger number of cardiovascular complications in a significant way. Conclusions: The implementation of statin therapy in the preoperative had a positive effect and it reduced in a significant way the morbidity and mortality during the intraoperative and postoperative immediate period in this type of patient.


REFERENCES

  1. Task Force in Preanesthesia Evaluation. Practice Advisory for Preanesthesia Evaluation. An update report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Anesthesiology 2012; 116: 522-538.

  2. Bakker EJ, Ravensbergen NJC, Poldermans D. Perioperative cardiac evaluation, monitoring and risk reduction strategies in noncardiac surgery patients. Curr Opin Crit Care 2011; 17: 409-15.

  3. Fernández A, Jiménez J, Bodí V, Barrabés JA. Actualización en cardiopatía isquémica. Rev Esp Cardiol 2012; 65(supl 1): 42 – 49.

  4. Brookes ZLS, McGown C, Reilly S. Statins for all: the new premed?. BJA 2009; 103: 99-107.

  5. González JR, Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC. Prevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en España: estudio DYSIS-España. Rev Esp Cardiol 2011; 64:286-94.

  6. Kersten J, Fleisher LA. Statins: the next in cardioprotection?. Anesthesiology 2006; 105: 1079-1080.

  7. Carrillo R, Sosa-García J. impacto de las estatinas en el periodo perioperatorio. Rev Mex Anest 2011; 34(1): 31 – 36.

  8. Aranda F. Reducción del riesgo perioperatorio en cirugía no cardíaca: rol de los beta-bloqueadores y las estatinas. Rev Chil Anest 2013; 42: 26-32.

  9. Chan YC, Cheng SW, Irwin MG. Perioperative use of statins in non-cardiac surgery. Vascular Health and Risk Management 2008; 4:75-81.

  10. Hindler K, Eltzschig HK, Fox AA. Influence of statins on perioperative outcomes. J Cardiothorac Vasc Anesth 2006; 20: 251-258.

  11. Ackerman M. Unmasking concealed long QT syndrome. Heart Rhythm. 2008; 5:8-10.

  12. Breijo FR, Pardo M, Alcaraz M. Asociación de intervalo PR corto, intervalo QT largo y muerte súbita en un varón joven. Rev Esp Cardiol 2010; 63(3): 362-76.

  13. Gadaleta FL, Llois S, Sinisi V, Quiles J, Avanzas P, Kaski JC. Prolongación del intervalo QT corregido: nuevo predictor de riesgo cardiovascular en el síndrome coronario agudo sin elevación del ST. Rev Esp Cardiol 2008; 61(6):572-8.

  14. Müller K, Zott M. Diagnóstico de isquemia e infarto perioperatorio. Rev Chil Anest 2013; 42: 48-54.

  15. Chacón R. Anestesia para el paciente cardiópata sometido a cirugía no cardiaca: revisión de “algunas” condiciones clínicas. Rev Chil Anest 2013; 42: 6-8

  16. Elosua R, Morales A. Determinación del riesgo cardiovascular total. Caracterización, modelización y objetivos de la prevención según el contexto sociogeográfico. Rev Esp Cardiol 2011; 11(E):2-12.

  17. Borrás X, Murga N, Ripoll T, Gómez JJ. Novedades en cardiología clínica: nuevos enfoques de viejos retos. Rev Esp Cardiol 2012; 65(Supl 1):65-72.

  18. Lobato E. Importancia de la isquemia intraoperatoria. Rev Mex Anestesiol 2011; 34(Supl 1): S243-S251.

  19. Pencina MJ, D’Agostino RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30- year risk of cardiovascular disease: the Framingham heart study. Circulation 2009; 119:3078-84.

  20. Richard F. Alcock. Perioperative myocardial necrosis in pa-tients at high cardiovascular risk undergoing elective non-cardiac surgery. Heart 2012; 98: 792-798.

  21. Camona R, Rizo GO, Chávez E. Mecanismos electrofisioló-gicos de la elevación del segmento ST durante el infarto agu-do de miocardio. Hipótesis actual. CorSalud 2010; 2(4): 247-253.

  22. O’Donnell CJ, Elosua R. Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study. Rev Esp Cardiol 2008; 61:299-310.

  23. Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.

  24. Cutodis F, Schirmer SH, Baumhäkel M. Vascular pathophys-iology in response to increased heart rate. J Am Coll Cardiol 2010; 56: 1973-1983.

  25. Kolloch R, Legler UF, Champion A, Cooper-DeHoff RM, Handberg E, Zhou Q, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery dis-ease: findings from the International Verapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29:1327-34.

  26. Kristal-Boneh E, Silber H, Harari G, Froom P. The associa-tion of resting heart rate with cardiovascular, cancer and all- cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2009; 21: 116-124.

  27. Ruiz M, Romo E, Mesa D, Delgado M, Ogayar C, Castillo JC, et al. Valor pronóstico de la frecuencia cardiaca en repo-so en una población general de pacientes con cardiopatía is-quémica crónica: un estudio prospectivo, monocéntrico de cohortes. Rev Esp Cardiol 2010; 63(11):1270-80.

  28. Glass P, Lubarsky D, McEvoy M. Anestésicos intravenosos no opioides. En: Miller R Anestesia. Madrid: Elsevier, 2005: 317-78

  29. Jiménez-Candil J, Cruz I, González JM, Albarrán C, Pabón P, Moriñigo JL, et al. Short- and long-term prognostic value of the corrected QT interval in the non-ST elevation acute coro-nary syndrome. J Electrocardiol 2007; 40: 180-7.

  30. Wojciech Z. Dispersion of ventricular repolarization and ar-rhythmic cardiac death in coronary artery disease. Am J Car-diol. 2004; 74:550-3.




2020     |     www.medigraphic.com